Prophylactic and Preemptive Therapy with Dasatinib after Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Abstract excerpt

To the Editor: Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) respond poorly to conventional chemotherapy, with reported long-term overall survival (OS) rates of ∼10%. Recent induction therapy based on tyrosine kinase inhibitors (TKIs), alone or in combination, has achieved complete response rates as high as 75%-95%; however, these promising results are transitory, and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Lymphoblastic Leukemia research
• Share to Chronic Myeloid Leukemia Treatments
• Share to Eosinophilic Disorders and Syndromes